"N\u00EDzkomolekul\u00E1rn\u00ED hepariny" . . "Mal\u00FD, Jaroslav" . . "molecular; heparins"@en . "Antithrombotic activity of low molecular weight heparins (LMWH) in subcutaneous application creates antithrombotic environment by several mechanisms:binds significantly to antithrombin,thus inhibits factor Xa more selectively;increases fibrinolysis;decreases a plasminogen activator inhibitor;increases tissue factor inhibitor,thus inhibits tissue factor and extrinsic coagulation system.LMWH are standardized according to the inhibition act. of factor Xa.However,preparations with higher anti Xa activity dont have demonstrably greater antithrombotic effect.In comparison to an unfractionated heparin it is used with an advantage in transplant medicine,in a treatment and prevention of vascular occlusions in tumours,in patients with thromboembolisms in cerebral area,in a prophylaxis and treatment of deep vein thrombosis in patients with ischaemic heart disease.LMWH expressly blocks a receptor of smooth muscle fibres thus interferes with their proliferation,which is used in patients following cor. angioplasty."@en . "1"^^ . "Intern\u00ED medic\u00EDna pro praxi" . "RIV/00216208:11150/04:00004723" . "CZ - \u010Cesk\u00E1 republika" . "1"^^ . "N\u00EDzkomolekul\u00E1rn\u00ED hepariny"@cs . "11150" . "Low molecular heparins"@en . "442;449" . "[6FA158F8CF53]" . "RIV/00216208:11150/04:00004723!RIV08-MSM-11150___" . . . . . . . . . "S" . "Antitrombotick\u00E1 aktivita n\u00EDzkomolekul\u00E1rn\u00EDch heparin\u016F (LMWH) v podko\u017En\u00EDm pod\u00E1n\u00ED vytv\u00E1\u0159\u00ED antitrombotick\u00E9 prost\u0159ed\u00ED v\u00EDce mechanizmy:a) v\u00FDznamn\u011B se v\u00E1\u017Ee na antitrombin a t\u00EDm selektivn\u011Bji inhibuje faktor Xa, b) zvy\u0161uje fibrinol\u00FDzu, c) sni\u017Euje inhibitor aktiv\u00E1toru plazminogenu, d) zvy\u0161uje inhibitor tk\u00E1\u0148ov\u00E9ho faktoru a t\u00EDm inhibuje tk\u00E1\u0148ov\u00FD faktor a zevn\u00ED koagula\u010Dn\u00ED syst\u00E9m. LMWH jsou standardizov\u00E1ny podle inhibi\u010Dn\u00ED aktivity k faktoru Xa. Prepar\u00E1ty s vy\u0161\u0161\u00ED aktivitou anti Xa v\u0161ak nemaj\u00ED prokazateln\u011B v\u011Bt\u0161\u00ED antitrombotick\u00FD efekt. LMWH se pou\u017E\u00EDv\u00E1 v mnoha odv\u011Btv\u00EDch medic\u00EDny. Oproti nefrakcionovan\u00E9mu heparinu jej lze s v\u00FDhodou pou\u017E\u00EDt v transplantologii, v l\u00E9\u010Db\u011B a prevenci c\u00E9vn\u00EDch uz\u00E1v\u011Br\u016F u n\u00E1dorov\u00FDch chorob, u nemocn\u00FDch s tromboembolismy v cerebr\u00E1ln\u00ED oblasti, v profylaxi a l\u00E9\u010Db\u011B hlubok\u00FDch \u017Eiln\u00EDch tromb\u00F3z u nemocn\u00FDch s ischemickou chorobou srde\u010Dn\u00ED. LMWH specificky blokuje receptor hladk\u00FDch svalov\u00FDch vl\u00E1ken (SMC receptor) a t\u00EDm br\u00E1n\u00ED jejich proliferaci, \u010Deho\u017E se vyu\u017E\u00EDv\u00E1 u nemocn\u00FDch po koron\u00E1rn\u00EDch angioplastik\u00E1ch." . . . "9" . "N\u00EDzkomolekul\u00E1rn\u00ED hepariny"@cs . "6" . "Antitrombotick\u00E1 aktivita n\u00EDzkomolekul\u00E1rn\u00EDch heparin\u016F (LMWH) v podko\u017En\u00EDm pod\u00E1n\u00ED vytv\u00E1\u0159\u00ED antitrombotick\u00E9 prost\u0159ed\u00ED v\u00EDce mechanizmy:a) v\u00FDznamn\u011B se v\u00E1\u017Ee na antitrombin a t\u00EDm selektivn\u011Bji inhibuje faktor Xa, b) zvy\u0161uje fibrinol\u00FDzu, c) sni\u017Euje inhibitor aktiv\u00E1toru plazminogenu, d) zvy\u0161uje inhibitor tk\u00E1\u0148ov\u00E9ho faktoru a t\u00EDm inhibuje tk\u00E1\u0148ov\u00FD faktor a zevn\u00ED koagula\u010Dn\u00ED syst\u00E9m. LMWH jsou standardizov\u00E1ny podle inhibi\u010Dn\u00ED aktivity k faktoru Xa. Prepar\u00E1ty s vy\u0161\u0161\u00ED aktivitou anti Xa v\u0161ak nemaj\u00ED prokazateln\u011B v\u011Bt\u0161\u00ED antitrombotick\u00FD efekt. LMWH se pou\u017E\u00EDv\u00E1 v mnoha odv\u011Btv\u00EDch medic\u00EDny. Oproti nefrakcionovan\u00E9mu heparinu jej lze s v\u00FDhodou pou\u017E\u00EDt v transplantologii, v l\u00E9\u010Db\u011B a prevenci c\u00E9vn\u00EDch uz\u00E1v\u011Br\u016F u n\u00E1dorov\u00FDch chorob, u nemocn\u00FDch s tromboembolismy v cerebr\u00E1ln\u00ED oblasti, v profylaxi a l\u00E9\u010Db\u011B hlubok\u00FDch \u017Eiln\u00EDch tromb\u00F3z u nemocn\u00FDch s ischemickou chorobou srde\u010Dn\u00ED. LMWH specificky blokuje receptor hladk\u00FDch svalov\u00FDch vl\u00E1ken (SMC receptor) a t\u00EDm br\u00E1n\u00ED jejich proliferaci, \u010Deho\u017E se vyu\u017E\u00EDv\u00E1 u nemocn\u00FDch po koron\u00E1rn\u00EDch angioplastik\u00E1ch."@cs . "N\u00EDzkomolekul\u00E1rn\u00ED hepariny" . "Low molecular heparins"@en . "576299" . . "1212-7299" . "8"^^ .